Brian Garibaldi, MD, MEHP, professor of Medicine and of Physiology at the Johns Hopkins University School of Medicine, has been named the Charles Horace Mayo Professor of Medicine and the inaugural director of the new Center for Bedside Medicine at Northwestern.
A two-year follow-up clinical trial found that a personalized cellular therapy treatment for relapsed or refractory B-cell lymphoma demonstrated high safety and improved overall survival in patients, according to findings published in Blood.
Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer — its hunger for cholesterol — and how to sneakily use that to destroy it.
A multidisciplinary team of investigators have engineered a more accurate model for studying the underlying mechanisms of atrial fibrillation and treatment response, according to findings published in Science Advances.
Scientists have discovered a neuronal pathway involved in how the brain encodes the transition to high-intensity fear response behaviors required for survival, according to a study published in Nature.
A neurotransmitter previously thought to only calm neurons may also play a role in waking them up, according to a study published in the journal PLOS Biology, a discovery which upends conventional theories of how the neurotransmitter works in the brain.
An analysis of NIH training grants has illustrated systematic disadvantages among the trainees who receive the awards.
Investigators at Northwestern Medicine and the Flatiron Institute have characterized how developing cells reorganize their cytoplasm as part of their growth, according to a study published in Nature Physics, a discovery which furthers the field’s understanding of basic cellular processes at the earliest stages of development.
Northwestern Medicine investigators have revealed new insights into the impact of neuronal structural diversity on neural computation, the basis of brain function, according to a recent study published in the Proceedings of the National Academy of Sciences.
Even mild and moderate side effects can contribute to patients with cancer discontinuing their treatment, according to an analysis recently published in the Journal of Clinical Oncology.